Abstract
Chemotherapy is one of the most frequently employed and reliable treatment options for the management of a variety of cancers. Taxanes (paclitaxel, docetaxel and cabazitaxel) are frequently prescribed to treat breast cancer, hormone refractory prostate cancer, non-small cell lung cancer and ovarian cancer. Most of the commercial products of taxanes are available as injectables, which are not patient compliant and are associated with frequent side effects like ototoxicity, baldness and neurotoxicity. Most of these concerns are ascribable to the presence of toxic solvents in these commercial formulations, which are used to solubilize these drug(s). However, there have been several attempts to develop toxic solvent free taxane formulations, especially employing novel drug delivery systems (NDDS). These systems have been reported to result in the advancement of anticancer activity, therapeutic index, stability, biocompatibility, tissue or organ targeting, encapsulation capacity, tissue permeability, oral bioavailability, reduced toxicity and reduced incidences of abnormal reactions, sustained and controlled release in comparison to the conventional solvent-based formulations. The review is an attempt to analyze the potential of NDDS-mediated taxane delivery for safer and effective cancer chemotherapy.
Keywords: Paclitaxel, Docetaxel, Cabazitaxel, Liposomes, Niosomes, Ethosomes, Mixed Micelles, CNTs, Dendrimers, Nanoparticles, Emulsions, NDDS.
Current Pharmaceutical Design
Title:Role of Colloidal Drug Delivery Carriers in Taxane-mediated Chemotherapy: A Review
Volume: 22 Issue: 33
Author(s): Pramod Kumar, Kaisar Raza, Lokesh Kaushik, Ruchi Malik, Shweta Arora and Om Prakash Katare
Affiliation:
Keywords: Paclitaxel, Docetaxel, Cabazitaxel, Liposomes, Niosomes, Ethosomes, Mixed Micelles, CNTs, Dendrimers, Nanoparticles, Emulsions, NDDS.
Abstract: Chemotherapy is one of the most frequently employed and reliable treatment options for the management of a variety of cancers. Taxanes (paclitaxel, docetaxel and cabazitaxel) are frequently prescribed to treat breast cancer, hormone refractory prostate cancer, non-small cell lung cancer and ovarian cancer. Most of the commercial products of taxanes are available as injectables, which are not patient compliant and are associated with frequent side effects like ototoxicity, baldness and neurotoxicity. Most of these concerns are ascribable to the presence of toxic solvents in these commercial formulations, which are used to solubilize these drug(s). However, there have been several attempts to develop toxic solvent free taxane formulations, especially employing novel drug delivery systems (NDDS). These systems have been reported to result in the advancement of anticancer activity, therapeutic index, stability, biocompatibility, tissue or organ targeting, encapsulation capacity, tissue permeability, oral bioavailability, reduced toxicity and reduced incidences of abnormal reactions, sustained and controlled release in comparison to the conventional solvent-based formulations. The review is an attempt to analyze the potential of NDDS-mediated taxane delivery for safer and effective cancer chemotherapy.
Export Options
About this article
Cite this article as:
Kumar Pramod, Raza Kaisar, Kaushik Lokesh, Malik Ruchi, Arora Shweta and Katare Prakash Om, Role of Colloidal Drug Delivery Carriers in Taxane-mediated Chemotherapy: A Review, Current Pharmaceutical Design 2016; 22 (33) . https://dx.doi.org/10.2174/1381612822666160524144926
DOI https://dx.doi.org/10.2174/1381612822666160524144926 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Docking Analysis of Flavonoid Compounds with Matrix Metalloproteinase- 8 for the Identification of Potential Effective Inhibitors
Letters in Drug Design & Discovery PEDF & Stem Cells: Niche vs. Nurture
Current Drug Delivery Ganoderma lucidum (Ling-zhi): The Impact of Chemistry on Biological Activity in Cancer
Current Bioactive Compounds Noncovalent Binding to DNA: Still a Target in Developing Anticancer Agents
Current Medicinal Chemistry Is there a Role for Bevacizumab in Non-Glial Tumors?
Current Drug Targets Apoptosis Signaling Pathways in Anticancer Therapy
Current Cancer Therapy Reviews Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non – small Cell Lung Cancer
Current Cancer Drug Targets Poly(ethylene glycol)-polypeptide Copolymer Micelles for Therapeutic Agent Delivery
Current Pharmaceutical Biotechnology Recent Development in Fluorescent Probes for Copper Ion Detection
Current Topics in Medicinal Chemistry Patent Selections:
Current Biomarkers (Discontinued) Aspirin: from a Historical Perspective
Recent Patents on Cardiovascular Drug Discovery CYP3A4-mediated Pharmacokinetic Interactions in Cancer Therapy
Current Drug Metabolism Management of Advanced Staged Ovarian Cancer in a National Cancer Center: Comparison of the Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy
Current Women`s Health Reviews Cancer Diagnosis and Treatment Guidance: Role of MRI and MRI Probes in the Era of Molecular Imaging
Current Pharmaceutical Biotechnology Rapid Assays for Quantitating Cytokine Gene Expression Without Target Amplification
Combinatorial Chemistry & High Throughput Screening Lysophospholipids: Their Generation, Physiological Role and Detection. Are They Important Disease Markers?
Mini-Reviews in Medicinal Chemistry Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area
Current Psychiatry Reviews pH-Gradient Incorporation of 9-Nitrocamptothecin in PEGylated Liposomes: Formulation Properties and Efficacy <i>In Vitro</i> and <i>In Vivo</i>
Pharmaceutical Nanotechnology Imaging Virus-Associated Cancer
Current Pharmaceutical Design Therapeutics Based on microRNA: A New Approach for Liver Cancer
Current Genomics